However, targeting the protein stability (i.e., Akt inhibitors) or PTM (i.e., monoclonal antibodies) could be a very interesting approach to inhibit the PD-1/PD-L1 interaction between all these cells in the tumor microenvironment. The gene discussed is PDCD1; the disease is neoplasm.